These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10820893)

  • 41. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.
    Vinogradova Y; Coupland C; Hippisley-Cox J
    BMJ; 2015 May; 350():h2135. PubMed ID: 26013557
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rebuilding confidence in oral contraceptives: a new imperative in family planning.
    Spitzer WO
    Br J Clin Pharmacol; 1996 May; 41(5):359-63. PubMed ID: 8735675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral contraceptives and venous thromboembolism: an epidemiological review.
    Lidegaard O
    Eur J Contracept Reprod Health Care; 1996; 1(1):13-20. PubMed ID: 9678133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives.
    Farmer RD; Lawrenson RA; Todd JC; Williams TJ; MacRae KD; Tyrer F; Leydon GM
    Br J Clin Pharmacol; 2000 Jun; 49(6):580-90. PubMed ID: 10848722
    [TBL] [Abstract][Full Text] [Related]  

  • 45. WHO scientific group meeting on cardiovascular disease and steroid hormone contraceptives.
    Wkly Epidemiol Rec; 1997 Nov; 72(48):361-3. PubMed ID: 9409187
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The new pills: awaiting the next generation of oral contraceptives.
    Klitsch M
    Fam Plann Perspect; 1992; 24(5):226-8. PubMed ID: 1426186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
    Endrikat J; Müller U; Düsterberg B
    Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined oral contraceptives: acceptability and effective use.
    Kubba A; Guillebaud J
    Br Med Bull; 1993 Jan; 49(1):140-57. PubMed ID: 8324604
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A clinician's response to the oral contraceptive thrombosis controversy.
    Speroff L
    Hum Reprod Update; 1999; 5(6):654-63. PubMed ID: 10652975
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Desogestrel, gestodene contraceptives may carry greater thromboembolic risk.
    Am J Health Syst Pharm; 1996 Feb; 53(3):228. PubMed ID: 8808016
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M; Røde A; Westergaard J
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Myocardial infarction and stroke in young women: what is the impact of oral contraceptives?
    Lewis MA
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S68-77. PubMed ID: 9753313
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral contraceptives and venous thromboembolism.
    Paul C
    N Z Med J; 1996 Nov; 109(1033):413-5. PubMed ID: 8941290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
    Chez RA
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1296-300. PubMed ID: 2524163
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effects on hemostasis of oral contraceptives containing desogestrel.
    Stubblefield PG
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1047-52. PubMed ID: 8447359
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral contraceptives, hormone therapy and cardiovascular risk.
    Shapiro S
    Climacteric; 2008 Oct; 11(5):355-63. PubMed ID: 18781479
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group.
    World Health Organ Tech Rep Ser; 1998; 877():i-vii, 1-89. PubMed ID: 9615606
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?
    Odlind V; Milsom I; Persson I; Victor A
    Acta Obstet Gynecol Scand; 2002 Jun; 81(6):482-90. PubMed ID: 12047300
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Hormonal contraception and vascular risk: CNGOF Contraception Guidelines].
    Plu-Bureau G; Sabbagh E; Hugon-Rodin J
    Gynecol Obstet Fertil Senol; 2018 Dec; 46(12):823-833. PubMed ID: 30389542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.